HKSE - Delayed Quote HKD

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)

Compare
8.620
-0.370
(-4.12%)
As of 10:40:30 AM GMT+8. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Yuelei Shen Ph.D. Chairman of the Board, CEO & GM 2.2M -- 1970
Dr. Jian Ni Executive Director -- -- 1972
Dr. Haichao Zhang Senior Operation Director of Animal Center & Executive Director 1.08M -- 1980
Mr. Bin Liu CFO & Deputy GM -- -- 1969
Dr. Yi Yang Chief Scientific Officer & Deputy GM -- -- 1978
Dr. Chaoshe Guo VP of Marketing & Deputy GM -- -- 1971
Ms. Chunli Sun Director of Human Resources & Supervisor -- -- 1980
Ms. Yan Li Chairman of the Supervisory Committee & Director of the President's Office -- -- 1989
Dr. Qingcong Lin Deputy GM & CEO of Biocytogen Boston Corp. -- -- 1965
Mr. Yongliang Wang Deputy GM, Joint Company Secretary & Chief Secretariat Officer -- -- 1985

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

12 Baoshen South Street
Daxing Bio-Medicine Industry Park Daxing District
Beijing
China
86 10 5696 7680 https://biocytogen.com.cn
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,040

Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences; and collaboration with Acepodia Inc. for development of dual-payload bispecific antibody-drug conjugates. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.

Corporate Governance

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.